StreetInsider.com News Articles

Form SCHEDULE 13G Gossamer Bio, Inc. Filed by: Opaleye Management Inc.

Wed, 29 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260729/26834912.html

Form SCHEDULE 13G Gossamer Bio, Inc. Filed by: Opaleye Management Inc.

Wed, 29 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260729/26834912.html

Form SCHEDULE 13G/A Gossamer Bio, Inc. Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:21:00 -0400

si-local-file:///var/storage/secattach/20260729/26834312.html

Form SCHEDULE 13G/A Gossamer Bio, Inc. Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:21:00 -0400

si-local-file:///var/storage/secattach/20260729/26834312.html

Leerink Upgrades Gossamer Bio Inc. (GOSS) to Outperform

Tue, 28 Jul 2026 02:36:09 -0400

Leerink analyst Joseph Schwartz upgraded Gossamer Bio Inc. (NASDAQ: GOSS) from Market Perform to Outperform with a price target of $1.00.

The analyst comments: “We are upgrading GOSS to Outperform from Market Perform based on valuation following today’s positive FDA feedback and our updated model. The FDA’s characterization of PROSERA’s statistical significance and magnitude of treatment effect as review rather than filing issues meaningfully reduces near-term regulatory uncertainty and supports GOSS' planned September 2026 NDA submission. We now assign a 50% US probability of success to seralutinib in pulmonary arterial hypertension (PAH) in the US, up from 20%, while maintaining 20%

Leerink Upgrades Gossamer Bio Inc. (GOSS) to Outperform

Tue, 28 Jul 2026 02:36:09 -0400

Leerink analyst Joseph Schwartz upgraded Gossamer Bio Inc. (NASDAQ: GOSS) from Market Perform to Outperform with a price target of $1.00.

Form 8-K Gossamer Bio, Inc. For: Jul 23

Mon, 27 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260727/26819430.html

Form 8-K Gossamer Bio, Inc. For: Jul 23

Mon, 27 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260727/26819430.html

Gossamer Bio plans NDA submission for seralutinib in September 2026

Mon, 27 Jul 2026 07:02:27 -0400

Gossamer Bio, Inc. (Nasdaq: GOSS) announced it plans to submit a New Drug Application (NDA) for seralutinib, a treatment for pulmonary arterial hypertension (PAH), in September 2026, following a Pre-NDA Type B meeting with the U.S. Food and Drug Administration (FDA) and receipt of official meeting minutes.

The FDA characterized the degree of statistical significance and the magnitude of the treatment effect observed in the Phase 3 PROSERA trial as review issues rather than filing issues. On that basis, Gossamer intends to support the NDA with data from the PROSERA study, the Phase 2 TORREY study, and supportive analyses. If the

Gossamer Bio plans NDA submission for seralutinib in September 2026

Mon, 27 Jul 2026 07:02:27 -0400

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.

Fri, 24 Jul 2026 21:15:00 -0400

si-local-file:///var/storage/secattach/20260724/26814567.html

Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.

Fri, 24 Jul 2026 21:15:00 -0400

si-local-file:///var/storage/secattach/20260724/26814567.html

Form 8-K Gossamer Bio, Inc. For: Jul 14

Wed, 15 Jul 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260715/26770307.html

Form 8-K Gossamer Bio, Inc. For: Jul 14

Wed, 15 Jul 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260715/26770307.html

Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.

Wed, 01 Jul 2026 21:24:00 -0400

si-local-file:///var/storage/secattach/20260701/26722782.html

Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.

Wed, 01 Jul 2026 21:24:00 -0400

si-local-file:///var/storage/secattach/20260701/26722782.html

Gossamer Bio sets conversion rate for 2030 convertible notes

Wed, 01 Jul 2026 09:03:04 -0400

Gossamer Bio, Inc. (NASDAQ: GOSS) has announced the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030, set at 5,347.5936 shares of common stock per $1,000 principal amount, representing a conversion price of approximately $0.19 per share.

The initial exercise price for the company's accompanying Purchase Warrants was set at $0.34 per whole share of common stock.

Both figures were determined using a "Reference Price" of $0.17, calculated over a seven trading-day period beginning June 22, 2026, in accordance with the terms of the notes and warrants.

The conversion rate was calculated as the lesser of 5,347.5936 or